Mitsubishi Tanabe Pharma America Unveils Data on RADICAVA ORS
Mitsubishi Tanabe Pharma America, Inc. (MTPA) is thrilled to share vital information regarding their innovative product, RADICAVA ORS (edaravone), at an upcoming event designed for specialized pharmacy professionals. This presentation aims at enhancing the understanding of it’s application in managing amyotrophic lateral sclerosis (ALS), a challenging neurodegenerative disease impacting countless lives.
Insights into ALS Treatment with RADICAVA ORS
At the National Association of Specialty Pharmacy (NASP) Annual Meeting, MTPA will provide extensive insights into recent findings from their ongoing research. The data will overview patient demographics, treatment duration, and progression milestones for individuals treated with RADICAVA ORS. These findings reflect comprehensive analyses that highlight the real-world impact of this medication on patients.
Understanding the Data Presentation
The insightful presentations will include data stemming from a real-world observational analysis that focuses not only on patient characteristics but also on treatment duration alongside progression milestones. These analyses emerge from the collaboration with Optum’s de-identified Clinformatics Data Mart, ensuring a rich understanding of how RADICAVA ORS impacts the treatment landscape for ALS patients.
Overview of Presentation Details
MTPA is hosting two significant presentations at the NASP Annual Meeting. The details will include:
- A Preliminary Analysis of Oral Edaravone-Treated Patients With Amyotrophic Lateral Sclerosis Enrolled in a US-Based Administrative Claims Database
Presented by Malgorzata Ciepielewska, M.S.; MTPA. Available during poster sessions scheduled from 12:30 p.m. – 3:00 p.m. and 7:00 a.m. – 8:00 a.m. on subsequent days. - Healthcare Resource Utilization of Oral Edaravone–Treated Patients With Amyotrophic Lateral Sclerosis Enrolled in a US-Based Administrative Claims Database
Also by Malgorzata Ciepielewska, M.S.; MTPA, presented during similar timings.
RADICAVA ORS - Treatment Overview
RADICAVA ORS has gained recognition in the medical community following its approval by the U.S. FDA for treating ALS. The oral formulation offers a manageable treatment regimen, making it easier for patients to adhere to prescribed therapies. It’s administered with particular protocols that demonstrate careful regard for patient comfort and convenience. Observational studies detailing the effectiveness and resource utilization of RADICAVA ORS are crucial for ensuring that it meets the diverse needs of ALS patients.
About Mitsubishi Tanabe Pharma America, Inc.
Mitsubishi Tanabe Pharma America, Inc. is a subsidiary of Mitsubishi Tanabe Pharma Corporation, dedicated to improving healthcare through pioneering research and development. The corporation has invested significantly in studying ailments affecting the nervous system, demonstrating a heartfelt commitment to patient care and innovative solutions.
Continued Commitment to ALS Patients
The commitment of MTPA to individuals struggling with ALS is unwavering. The company dedicates resources and expertise to ensure that their treatments not only provide relief but also enhance the overall quality of life for those living with this debilitating condition. The insights shared at the NASP Annual Meeting are a testament to their engaging research efforts and patient-driven ethos.
Frequently Asked Questions
What is RADICAVA ORS?
RADICAVA ORS is an oral formulation of edaravone designed to treat amyotrophic lateral sclerosis (ALS), making the treatment process more accessible for patients.
When will the data presentations occur at the NASP Annual Meeting?
The presentations are scheduled for the 2024 NASP Annual Meeting, with specific poster session times noted for each presentation.
Who is presenting the findings on RADICAVA ORS?
Malgorzata Ciepielewska, M.S. from Mitsubishi Tanabe Pharma America will present the findings about RADICAVA ORS.
What observations are explored regarding RADICAVA ORS?
The presentations delve into patient demographics, treatment duration, clinical characteristics, and healthcare resource utilization concerning RADICAVA ORS.
How can RADICAVA ORS benefit ALS patients?
RADICAVA ORS is designed to ease the treatment regimen for ALS patients, potentially enhancing adherence and improving clinical outcomes while minimizing the burden of care.
